Impact of Different Levels of IPTH on All-Cause Mortality in Dialysis Patients with Secondary Hyperparathyroidism After Parathyroidectomy
Overview
Biotechnology
General Medicine
Authors
Affiliations
Background: Secondary hyperparathyroidism (SHPT) usually required parathyroidectomy (PTX) when drugs treatment is invalid. Analysis was done on the impact of different intact parathyroid hormone (iPTH) after the PTX on all-cause mortality.
Methods: An open, retrospective, multicenter cohort design was conducted. The sample included 525 dialysis patients with SHPT who had undergone PTX.
Results: 404 patients conformed to the standard, with 36 (8.91%) deaths during the 11 years of follow-up. One week postoperatively, different levels of serum iPTH were divided into four groups: A: ≤20 pg/mL; B: 21-150 pg/mL; C: 151-600 pg/mL; and D: >600 pg/mL. All-cause mortality in groups with different iPTH levels appeared as follows: A (8.29%), B (3.54%), C (10.91%), and D (29.03%). The all-cause mortality of B was the lowest, with D the highest. We used group A as reference (hazard ratio (HR) = 1) compared with the other groups, and HRs on groups B, C, and D appeared as 0.57, 1.43, and 3.45, respectively.
Conclusion: The all-cause mortality was associated with different levels of iPTH after the PTX. We found that iPTH > 600 pg/mL appeared as a factor which increased the risk of all-cause mortality. When iPTH levels were positively and effectively reducing, the risk of all-cause mortality also decreased. The most appropriate level of postoperative iPTH seemed to be 21-150 pg/mL.
Association between serum intact parathyroid hormone and survival in dialysis patients.
Luo C, Bian X, Ji C, Wang H, Ma J, Zhong C Int Urol Nephrol. 2024; 57(3):1019-1028.
PMID: 39557805 DOI: 10.1007/s11255-024-04288-y.
Wang L, Li Y, Liu X, Hou B, Xu Y Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(5):784-794.
PMID: 39174892 PMC: 11341229. DOI: 10.11817/j.issn.1672-7347.2024.240064.
Gan L, Wang L, Li W, Zhang Y, Xu B Front Endocrinol (Lausanne). 2024; 15:1406690.
PMID: 39027473 PMC: 11254665. DOI: 10.3389/fendo.2024.1406690.
Gong X, Wang Y, Li C, Liao X, Li S, Yang L Int Urol Nephrol. 2022; 55(5):1239-1245.
PMID: 36331700 PMC: 10105684. DOI: 10.1007/s11255-022-03401-3.
Guo W, Zhang H, Zhang Y, Huang H, Liu W, Diao Z Front Endocrinol (Lausanne). 2022; 13:869330.
PMID: 35634511 PMC: 9136015. DOI: 10.3389/fendo.2022.869330.